Lung Cancer – Biocept

Detection of EGFR Mutations in Quantity Insufficient Tissue Slides by High Sensitivity Assay Target Selector™ in Patients with Non-Small Cell Lung Cancer

Molecular Med Tri-Con 2021

BioceptApril 9, 2021

Utility of Liquid Biopsy in Diagnosis and Treatment Response in EGFR Mutant NSCLC Patients with Leptomeningeal Involvement

International Association for the Study of Lung Cancer (IASLC) 2020

BioceptMay 9, 2020

Target Selector™ cerebrospinal fluid (CSF) circulating tumor cells and biomarker analysis: improving sensitivity and targeted treatment options in breast and NSCLC cancer patients with CNS involvement

Society for Neuro-Oncology 2020

BioceptApril 9, 2020

Clinical utility of circulating tumor cell (CTC) analysis in patients with metastatic NSCLC receiving first-line chemotherapy

University of Missouri at Kansas City, Kansas City 2019

BioceptAugust 9, 2019

Analytical validation of the Target Selector ctDNA platform featuring single copy detection sensitivity for clinically actionable EGFR, BRAF, and KRAS mutations

PLOS ONE 2019

BioceptJune 9, 2019

Demonstrated Clinical Utility of Target Selector™ ctDNA Testing: Liquid Biopsy EGFR Mutation Detection Enabled Targeted Therapy Selection for Three Advanced NSCLC

Clinics in Oncology - General Oncology 2019

BioceptMay 9, 2019

Validation of Target Selector™ Next Generation Sequencing Lung Panelfor the Detection of Circulating Tumor TNA Alterations

AMP 2019

BioceptApril 9, 2019

The Dynamic Range of Mutant Allele Fraction Detected in Patients with NSCLC: Clinical Experience Data and Clinical Implications

World Conference in Lung Cancer 2019

BioceptFebruary 9, 2019

Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer

Oncology & Hematology Review 2018

BioceptJuly 9, 2018

Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM

World Conference in Lung Cancer 2018

BioceptMarch 9, 2018